---
document_datetime: 2023-09-21 19:11:39
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/pedea-epar-procedural-steps-taken-authorisation_en.pdf
document_name: pedea-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.670157
conversion_datetime: 2025-12-19 10:58:08.568594
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant  Orphan  Europe  SARL  submitted  on  8  May  2003  an  application  for  Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Pedea, through  the  centralised  procedure.  After  agreement  by  the  CPMP  on  16  November  2000,  this medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993 as amended.

Pedea was designated as an orphan medicinal product EU/3/01/20 on 14 February 2001.

| The Rapporteur and Co-Rapporteur appointed by the CPMP were:   | The Rapporteur and Co-Rapporteur appointed by the CPMP were:   | The Rapporteur and Co-Rapporteur appointed by the CPMP were:   |
|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
| Rapporteur:                                                    | Dr D. Lyons                                                    | Dr I. Hudson                                                   |

## Orphan Drugs:

Ibuprofen was designated as an orphan medicinal product in the following indication: Treatment of Patent  Ductus  Arteriosus.  The  calculated  prevalence  of  this  condition  was  2.13  per  10,000  EU populations.

## Scientific Advice:

The applicant did not seek scientific advice at the CPMP.

## Licensing status:

The product was not licensed in any country at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The procedure started on 21 July 2003.
- The Rapporteur's first Assessment Report was circulated to all CPMP members on 1 October 2003. The Co-Rapporteur's first Assessment Report was circulated to all CPMP members on 29 September 2003.
- During the CPMP meeting on 18 - 20 November 2003, the CPMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on  21 November 2003.
- The  applicant  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on  13 January 2004.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CPMP members on 25 February 2004.
- During the CPMP meeting on 23-24 March 2004, the CPMP agreed on a List of Outstanding Issues to be addressed in writing by the applicant.
- The applicant submitted written responses to the CPMP List of Outstanding Issues on 5 April 2004.
- The  Rapporteurs  circulated  the  Joint  Review  on  the  applicant's  responses  to  the  List  of Outstanding Issues to all CPMP members on  16 April 2004.
- During  the  meeting  on  20  -  22  April  2004,  the  CPMP,  in  the  light  of  the  overall  data  and justifications  submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive opinion  for  granting  a  Marketing  Authorisation  to  Pedea  on  22  April  2004.  The  applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 20 April 2004.
- The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 29 July 2004.